RFG Advisory’s ImmunityBio IBRX Stock Holding History

RFG Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-39,084	Closed	-$103K	–	985
2025 Q2	$103K	Buy	+39,084	New	+$105K	﹤0.01%	913

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

RFG Advisory's IBRX Position: Q3 2025 in Review

RFG Advisory sold out of ImmunityBio (IBRX) in Q3 2025, closing a stake of 39,084 shares — an estimated $103K sold.

RFG Advisory first reported a position in IBRX in Q2 2025 and held it in 1 quarter. The position peaked at $103K in Q2 2025. 264 funds tracked by Wall St. Rank hold IBRX as of Q3 2025.

RFG Advisory reported no remaining ImmunityBio position as of Q3 2025 after selling out during the quarter.
RFG Advisory sold 39,084 ImmunityBio shares in Q3 2025, an estimated $103K.
RFG Advisory first reported a position in ImmunityBio in Q2 2025 and held it in 1 quarter.
RFG Advisory's ImmunityBio position peaked at $103K in Q2 2025.
264 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2025.

Based on RFG Advisory's 13F filing for Q3 2025, filed 6 Nov 2025.